Chengyi Pharmaceuticals (603811.SH) released its semi-annual financial results, with a net profit attributable to shareholders of 1.12 billion yuan, a year-on-year increase of 47.03%.

Wise Finance News App, Chengyi Pharmaceutical (603811.SH) disclosed its 2025 interim report, reporting a revenue of 417 million yuan during the reporting period, a year-on-year increase of 17.11%; net profit attributable to parent company of 112 million yuan, a year-on-year increase of 47.03%; non-net profit deducted 111 million yuan, a year-on-year increase of 54.21%; and basic earnings per share of 0.35 yuan.